Our Mission >>
AACE Obesity and Nutrition Conference 2022
4-6 February 2022
Diabetes UK Professional Conference 2022
7-11 March 2022
ON DEMAND PROGRAMS
“Practical Applications in Managing Patients with CardioRenal Disease: New SGLT-2 Study Data” was a recent symposium produced by Worldwide CardioDiabetes and held in conjunction with the 76th Annual Brazilian Congress of Cardiology in November 2021. It is now available here for open, on-demand access. We encourage you to view the program in order to learn more about the results of recent studies and how to apply this knowledge to your daily practice.
Cardiorenal syndrome (CRS) in people with type 2 diabetes mellitus illustrates the bidirectional link between the heart and the kidneys, with acute or chronic dysfunction of one organ adversely impacting the function of the other. The cardiovascular and renoprotective benefits evidenced with sodium-glucose transporter-2 (SGLT-2) inhibitors make them a potential choice in the management of CRS.
Click here to view the program. After viewing, be sure to access the program evaluations.
The virtual symposium “Reaching Therapeutic Goals in Type 2 Diabetes: New Options” was held in conjunction with the 55th Congress of the German Diabetes Society (DDG) on May 13, 2021. The 90-minute program featured Drs. Petra-Maria Schumm-Draeger (Munich) and Andrew J.M. Boulton (Manchester) as co-chairs, with vibrant presentations by Drs. Boulton, Brian Frier (Edinburgh), Paolo Pozzilli (Rome), and Oliver Schnell (Munich-Neuherberg). All presentations are available on demand for viewing per the links below. In addition, copies of the slides are available upon return of a short survey.
Click here to access the presentation videos.
Click here to access the survey.
“Reaching Therapeutic Goals in Type 2 Diabetes” was held as a live webinar on January 27, 2021 and is now available on-demand. This webinar features prominent international speakers from England, India, and Kuwait, and a lively question and answer session. We invite you to participate in this virtual program as well as read the live webinar blog posts written by the speakers. The posts contain current information about proven approaches to preventing hypoglycemia, fixed dose combination treatments in managing type 2 diabetes, the impact of uncontrolled diabetes on overall cardiovascular health, the challenges in treating the global burden of diabetes, and how to optimize type 2 diabetes treatment results amidst the COVID-19 pandemic.
Click here to review the Recorded Program.
Worldwide Diabetes held a live webinar on November 28, 2020 in conjunction with the 34th Congresso Brasileiro de Endocrinolgia e Metabologia (a virtual event). “Advancing Strategies in the Management of Type 2 Diabetes” featured speakers from Belgium, Brazil, England, and the United States and included presentations on preventing hypoglycemia, new uses of insulin, the psychological aspects of patient adherence, and how recent results of cardiovascular outcomes trials point to new treatment options. The webinar is now available on demand.
Click here to view the program.
In her latest column, Dr. Pei Lin Chan focuses on the rise in end-stage renal disease among patients with type 2 diabetes. She discusses several recent clinical studies that have shown delays and reductions in renal complications as well as cardiorenal protection. Please take a moment to read her column and check back here for her continuing editorial contributions.
Click here to read the column.
Click here for Dr. Chan’s previous columns.
Worldwide Cardio Diabetes held a virtual symposium during the recent 7th International Conference on Prehypertension, Hypertension, Metabolic Disorders and Cardiovascular Disease and it is now available on demand. “Diabetes and CardioRenal Disease: Can We Reduce the Impact of this Deadly Combination” features presentations by Drs. Andrew Boulton, George Bakris, Martin Rutter, and Philip Home, delving into the important topics of the kidney and cardiovascular risk, treating heart failure, and improving outcomes in diabetes beyond glucose control therapies.
Click here to view the program.